BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 25867866)

  • 1. Toxicity profile and treatment delays in NOPHO ALL2008-comparing adults and children with Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Toft N; Birgens H; Abrahamsson J; Griškevičius L; Hallböök H; Heyman M; Klausen TW; Jónsson ÓG; Palk K; Pruunsild K; Quist-Paulsen P; Vaitkeviciene G; Vettenranta K; Asberg A; Helt LR; Frandsen T; Schmiegelow K
    Eur J Haematol; 2016 Feb; 96(2):160-9. PubMed ID: 25867866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia.
    Toft N; Birgens H; Abrahamsson J; Griškevičius L; Hallböök H; Heyman M; Klausen TW; Jónsson ÓG; Palk K; Pruunsild K; Quist-Paulsen P; Vaitkeviciene G; Vettenranta K; Åsberg A; Frandsen TL; Marquart HV; Madsen HO; Norén-Nyström U; Schmiegelow K
    Leukemia; 2018 Mar; 32(3):606-615. PubMed ID: 28819280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maintenance therapy and risk of osteonecrosis in children and young adults with acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study.
    Toksvang LN; Andrés-Jensen L; Rank CU; Niinimäki R; Nersting J; Nielsen SN; Mogensen SS; Harila-Saari A; Abrahamsson J; Joelsson J; Overgaard UM; Quist-Paulsen P; Griškevičius L; Jónsson ÓG; Vaitkevičienė G; Frandsen TL; Toft N; Grell K; Schmiegelow K
    Cancer Chemother Pharmacol; 2021 Nov; 88(5):911-917. PubMed ID: 34145469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk group assignment differs for children and adults 1-45 yr with acute lymphoblastic leukemia treated by the NOPHO ALL-2008 protocol.
    Toft N; Birgens H; Abrahamsson J; Bernell P; Griškevičius L; Hallböök H; Heyman M; Holm MS; Hulegårdh E; Klausen TW; Marquart HV; Jónsson OG; Nielsen OJ; Quist-Paulsen P; Taskinen M; Vaitkeviciene G; Vettenranta K; Åsberg A; Schmiegelow K
    Eur J Haematol; 2013 May; 90(5):404-12. PubMed ID: 23461707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing osteonecrosis clinical phenotype, timing, and risk factors in children and young adults treated for acute lymphoblastic leukemia.
    Mogensen SS; Harila-Saari A; Mäkitie O; Myrberg IH; Niinimäki R; Vestli A; Hafsteinsdottir S; Griškevicius L; Saks K; Hallböök H; Retpen J; Helt LR; Toft N; Schmiegelow K; Frandsen TL;
    Pediatr Blood Cancer; 2018 Oct; 65(10):e27300. PubMed ID: 29943905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial.
    Nielsen SN; Grell K; Nersting J; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Vaitkeviciene G; Pruunsild K; Hjalgrim LL; Schmiegelow K
    Lancet Oncol; 2017 Apr; 18(4):515-524. PubMed ID: 28258828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Acute lymphoblastic leukaemia in Danish children and young people 10 to 19 years of age. Should young adults with acute lymphoblastic leukaemia be treated in the same way as children?].
    Schrøder H; Kjeldstad M; Boesen AM; Nielsen OJ; Schmidt KG; Johnsen HE; Gregersen H; Gustafsson G
    Ugeskr Laeger; 2006 Jun; 168(26-32):2554-8. PubMed ID: 16824410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96.
    Ribera JM; Oriol A; Sanz MA; Tormo M; Fernández-Abellán P; del Potro E; Abella E; Bueno J; Parody R; Bastida P; Grande C; Heras I; Bethencourt C; Feliu E; Ortega JJ
    J Clin Oncol; 2008 Apr; 26(11):1843-9. PubMed ID: 18398150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol.
    Henriksen LT; Harila-Saari A; Ruud E; Abrahamsson J; Pruunsild K; Vaitkeviciene G; Jónsson ÓG; Schmiegelow K; Heyman M; Schrøder H; Albertsen BK;
    Pediatr Blood Cancer; 2015 Mar; 62(3):427-33. PubMed ID: 25418987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute lymphoblastic leukemia in adolescents between 10 and 19 years of age in Denmark--secondary publication.
    Schrøder H; Kjeldahl M; Boesen AM; Nielsen OJ; Schmidt K; Johnsen HE; Gregersen H; Heyman M; Gustafsson G
    Dan Med Bull; 2006 Feb; 53(1):76-9. PubMed ID: 16761337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and toxicity of a paediatric protocol in teenagers and young adults with Philadelphia chromosome negative acute lymphoblastic leukaemia: results from UKALL 2003.
    Hough R; Rowntree C; Goulden N; Mitchell C; Moorman A; Wade R; Vora A
    Br J Haematol; 2016 Feb; 172(3):439-51. PubMed ID: 26683485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asparaginase-associated pancreatitis in children with acute lymphoblastic leukaemia in the NOPHO ALL2008 protocol.
    Raja RA; Schmiegelow K; Albertsen BK; Prunsild K; Zeller B; Vaitkeviciene G; Abrahamsson J; Heyman M; Taskinen M; Harila-Saari A; Kanerva J; Frandsen TL;
    Br J Haematol; 2014 Apr; 165(1):126-33. PubMed ID: 24428625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.
    Ribera JM; Ortega JJ; Oriol A; Granada I; Hernández-Rivas JM; Parody R; Bethencourt C; Rivas C; Bastida P; del Potro E; González-Valentín ME; Moreno MJ; Besalduch J; Fernández-Calvo J; Tormo M; Arias J; Molinés A; Sanz MA; Maldonado J; Millá F; Feliu E; San Miguel JF;
    Haematologica; 2002 Feb; 87(2):154-66. PubMed ID: 11836166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation.
    Marshall GM; Dalla Pozza L; Sutton R; Ng A; de Groot-Kruseman HA; van der Velden VH; Venn NC; van den Berg H; de Bont ES; Maarten Egeler R; Hoogerbrugge PM; Kaspers GJ; Bierings MB; van der Schoot E; van Dongen J; Law T; Cross S; Mueller H; de Haas V; Haber M; Révész T; Alvaro F; Suppiah R; Norris MD; Pieters R
    Leukemia; 2013 Jul; 27(7):1497-503. PubMed ID: 23407458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial.
    Mattano LA; Devidas M; Nachman JB; Sather HN; Hunger SP; Steinherz PG; Gaynon PS; Seibel NL;
    Lancet Oncol; 2012 Sep; 13(9):906-15. PubMed ID: 22901620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Ravandi F; O'Brien SM; Cortes JE; Thomas DM; Garris R; Faderl S; Burger JA; Rytting ME; Ferrajoli A; Wierda WG; Verstovsek S; Champlin R; Kebriaei P; McCue DA; Huang X; Jabbour E; Garcia-Manero G; Estrov Z; Kantarjian HM
    Cancer; 2015 Dec; 121(23):4158-64. PubMed ID: 26308885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute lymphoblastic leukemia in adolescents and young adults in Finland.
    Usvasalo A; Räty R; Knuutila S; Vettenranta K; Harila-Saari A; Jantunen E; Kauppila M; Koistinen P; Parto K; Riikonen P; Salmi TT; Silvennoinen R; Elonen E; Saarinen-Pihkala UM
    Haematologica; 2008 Aug; 93(8):1161-8. PubMed ID: 18556413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intermittent Versus Continuous PEG-Asparaginase to Reduce Asparaginase-Associated Toxicities: A NOPHO ALL2008 Randomized Study.
    Albertsen BK; Grell K; Abrahamsson J; Lund B; Vettenranta K; Jónsson ÓG; Frandsen TL; Wolthers BO; Heyman M; Schmiegelow K
    J Clin Oncol; 2019 Jul; 37(19):1638-1646. PubMed ID: 30978155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
    Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
    Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
    Schmiegelow K; Heyman M; Kristinsson J; Mogensen UB; Rosthøj S; Vettenranta K; Wesenberg F; Saarinen-Pihkala U;
    J Pediatr Hematol Oncol; 2009 Jun; 31(6):385-92. PubMed ID: 19648786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.